Decreasing incidence of femoral neck fractures in the Medicare population.

This study was designed to evaluate trends in incidence and treatment patterns for intracapsular hip fractures and to evaluate risk factors for complications and mortality. Patients with an intracapsular hip fracture who underwent internal fixation, hemiarthroplasty, or total hip arthroplasty (THA) were identified from a 5% nationwide sample of Medicare data (1998-2007). The authors identified 41,053 patients with intracapsular hip fractures between 1998 and 2007. The number of intracapsular hip fractures treated with internal fixation, hemiarthroplasty, or THA decreased by 21.8%, from 4602 in 1998 to 3601 in 2007. In 2007, 54.3% of patients with an intracapsular hip fracture were treated with hemiarthroplasty, compared with 41.2% who were treated with internal fixation and 4.5% who were treated with THA. Compared with internal fixation, hemiarthroplasty had higher adjusted risks of dislocation (+98%) and infection (+53%) at 90 days and higher rates of death (+8%) and reoperation (+33%) at 1 year. Patients who underwent THA had a higher risk of complications at 90 days compared with those who underwent hemiarthroplasty, with 114%, 39%, and 123% greater risk of dislocation, deep venous thrombosis, and mechanical complications, respectively. At 1 year, patients treated with THA had a 42% lower mortality risk and an 85% lower risk of reoperation compared with those who underwent internal fixation. Primary THA is performed more often in younger patients with fewer comorbidities. The incidence of intracapsular hip fracture decreased by 21.8% over the past decade. This decrease is likely the result of multiple factors, most significantly increased awareness and medical management of osteoporosis.

[1]  L. Melton,et al.  Trends in Fracture Incidence: A Population‐Based Study Over 20 Years , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  N. Yurgin,et al.  Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US , 2013, Applied Health Economics and Health Policy.

[3]  Aitao Guo,et al.  Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women , 2013, The Journal of international medical research.

[4]  R. Josse,et al.  Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis , 2013, Current medical research and opinion.

[5]  F. Frihagen,et al.  Hemiarthroplasty compared to internal fixation with percutaneous cannulated screws as treatment of displaced femoral neck fractures in the elderly: cost-utility analysis performed alongside a randomized, controlled trial , 2012, Osteoporosis International.

[6]  Mark Stevenson,et al.  Hemiarthroplasty and total hip arthroplasty for treating primary intracapsular fracture of the hip: a systematic review and cost-effectiveness analysis. , 2011, Health technology assessment.

[7]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[8]  S. Cummings,et al.  Secular trends in the incidence of hip and other osteoporotic fractures , 2011, Osteoporosis International.

[9]  S. Molyneux,et al.  The hidden blood loss after hip fracture. , 2011, Injury.

[10]  N. Mahomed,et al.  Fractures in the elderly: when is hip replacement a necessity? , 2010, Clinical interventions in aging.

[11]  D. Ford,et al.  One-year outcome for elderly patients with displaced intracapsular fractures of the femoral neck managed non-operatively. , 2010, Injury.

[12]  Colin D J Hopley,et al.  Primary total hip arthroplasty versus hemiarthroplasty for displaced intracapsular hip fractures in older patients: systematic review , 2010, BMJ : British Medical Journal.

[13]  M. Weaver,et al.  The Orthopaedic Implications of Diphosphonate Therapy , 2010, The Journal of the American Academy of Orthopaedic Surgeons.

[14]  Edmund Lau,et al.  Risk of Subsequent Revision after Primary and Revision Total Joint Arthroplasty , 2010, Clinical orthopaedics and related research.

[15]  S. Kurtz,et al.  Risk of Complication and Revision Total Hip Arthroplasty Among Medicare Patients with Different Bearing Surfaces , 2010, Clinical orthopaedics and related research.

[16]  T. Prevost,et al.  Symptomatic venous thromboembolism following a hip fracture , 2009, Acta orthopaedica.

[17]  T. Therneau,et al.  Secular trends in hip fracture incidence and recurrence , 2009, Osteoporosis International.

[18]  J. Zuckerman,et al.  Surgical Management of Hip Fractures: An Evidence‐based Review of the Literature. I: Femoral Neck Fractures , 2008, The Journal of the American Academy of Orthopaedic Surgeons.

[19]  F. McKiernan,et al.  Severely suppressed bone turnover and atypical skeletal fragility. , 2008, The Journal of clinical endocrinology and metabolism.

[20]  L. Carbone,et al.  Longitudinal Trends in Use of Bone Mass Measurement Among Older Americans, 1999–2005 , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .

[22]  N. Watts,et al.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.

[23]  S. Kurtz,et al.  Future clinical and economic impact of revision total hip and knee arthroplasty. , 2007, The Journal of bone and joint surgery. American volume.

[24]  A. Lombardi,et al.  Total hip arthroplasty after failed hip fractures: a challenging act. , 2007, Orthopedics.

[25]  O. Furnes,et al.  Total hip replacement after femoral neck fractures in elderly patients : Results of 8,577 fractures reported to the Norwegian Arthroplasty Register , 2007, Acta orthopaedica.

[26]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[27]  P. Kannus,et al.  Nationwide Decline in Incidence of Hip Fracture , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  J. Forbes,et al.  Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. , 2006, The Journal of bone and joint surgery. American volume.

[29]  O. Johnell,et al.  Primary arthroplasty is better than internal fixation of displaced femoral neck fractures: A meta-analysis of 14 randomized studies with 2,289 patients , 2006, Acta orthopaedica.

[30]  C. Samama,et al.  Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study 1,2 , 2005, Journal of thrombosis and haemostasis : JTH.

[31]  Linda Altizer,et al.  Hip fractures , 2005, Orthopedic nursing.

[32]  G. Hawker,et al.  Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the Hip Fracture Projections Wrong? , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[34]  K. Gurusamy,et al.  Internal fixation implants for intracapsular hip fractures in adults , 2001 .

[35]  W. Gillespie Hip fracture , 2001, BMJ : British Medical Journal.

[36]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[37]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[38]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[39]  M ROBURN,et al.  Femoral neck fractures. , 1964, Lancet.

[40]  O. Törring,et al.  Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[41]  J. Dungan Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur , 2011 .

[42]  B. Morrey Comparison of Bipolar Hemiarthroplasty with Total Hip Arthroplasty for Displaced Femoral Neck Fractures: A Concise Four-Year Follow-up of a Randomized Trial , 2011 .

[43]  K. Gurusamy,et al.  Cemented versus uncemented hemiarthroplasty for intracapsular hip fractures: A randomised controlled trial in 400 patients. , 2010, The Journal of bone and joint surgery. British volume.

[44]  J. Dungan Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis , 2010 .

[45]  J. Schneider Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. , 2009, Geriatrics.

[46]  A Heinonen,et al.  Epidemiology of hip fractures. , 1996, Bone.

[47]  K. Choi [Hip fracture]. , 1963, [Chapchi] Journal. Taehan Oekwa Hakhoe.